Evidence map›Paper›PMID 36993962›Full record

ArticleFrontiers in immunology2023

Proteomic characterisation of perhexiline treatment on THP-1 M1 macrophage differentiation.

Bimala Dhakal, Celine Man Ying Li, Mahnaz Ramezanpour, Ghais Houtak, Runhao Li, George Bouras, Alex Collela, Nusha Chegeni, Tim Kennion Chataway, Paul Drew and 6 more

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Bimala DhakalDiscipline of Surgery, Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.
Celine Man Ying LiDiscipline of Surgery, Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.
Mahnaz RamezanpourDiscipline of Surgery, Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.
Ghais HoutakDiscipline of Surgery, Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.
Runhao LiDiscipline of Surgery, Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.
George BourasDiscipline of Surgery, Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.
Alex CollelaFlinders Omics Facility, Department of Human Physiology, Flinders University, Adelaide, SA, Australia.
Nusha ChegeniFlinders Omics Facility, Department of Human Physiology, Flinders University, Adelaide, SA, Australia.
Tim Kennion ChatawayFlinders Omics Facility, Department of Human Physiology, Flinders University, Adelaide, SA, Australia.
Paul DrewDiscipline of Surgery, Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.
Benedetta C SallustioThe Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Adelaide, SA, Australia.
Sarah VreugdeDiscipline of Surgery, Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.
Eric SmithDiscipline of Surgery, Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.
Guy MaddernDiscipline of Surgery, Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.
Giovanni LicariThe Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Adelaide, SA, Australia.
Kevin FenixDiscipline of Surgery, Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.
Basil Hetzel Institute · AUFlinders University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Dysregulated inflammation is important in the pathogenesis of many diseases including cancer, allergy, and autoimmunity. Macrophage activation and polarisation are commonly involved in the initiation, maintenance and resolution of inflammation. Perhexiline (PHX), an antianginal drug, has been suggested to modulate macrophage function, but the molecular effects of PHX on macrophages are unknown. In this study we investigated the effect of PHX treatment on macrophage activation and polarization and reveal the underlying proteomic changes induced. Methods: We used an established protocol to differentiate human THP-1 monocytes into M1 or M2 macrophages involving three distinct, sequential stages (priming, rest, and differentiation). We examined the effect of PHX treatment at each stage on the polarization into either M1 or M2 macrophages using flow cytometry, quantitative polymerase chain reaction (qPCR) and enzyme linked immunosorbent assay (ELISA). Quantitative changes in the proteome were investigated using data independent acquisition mass spectrometry (DIA MS). Results: PHX treatment promoted M1 macrophage polarization, including increased Conclusion: This is the first study to report on the action of PHX on THP-1 macrophage polarization and the associated changes in the proteome of these cells.

Indexed as

PerhexilineProteomicsCell DifferentiationHumansInflammationMacrophagesProteomePerhexilineProteomeM1 macrolphagemacrophage polarisationperhexilinequantitative proteomicsTHP-1 derived macrophages

Identifiers

PMID36993962
PMCPMC10040681
OpenAlexW4324086267

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read43
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.